Abstract A series of novel (isopropylidene) uridine-[1,2,3]triazole hybrids (3a-3n) were efficiently synthesized via the copper-catalyzed azide-alkyne cycloaddition (CuAAC) from N-propargyl 2 0 ,3 0 -O-(isopropylidene) uridine with different aryl azides. All the synthesized compounds were screened for their in vitro anticancer and antibacterial activities. The anticancer activity results revealed that compounds 3d and 3f have registered equipotent activity against MCF-7 and 3n has shown excellent activity against HeLa in comparison with the standard drug Cisplatin. Remaining compounds have shown moderate to good anticancer activity against MCF-7 and HeLa cell lines. The antibacterial activity screening results revealed that, compounds 3b and 3n have shown excellent inhibition against Escherichia coli and Bacillus subtilis, 3d against Proteus vulgaris, 3k against Staphylococcus aureus and 3l against S. aureus and B. subtilis have shown equipotent activity in comparison with the standard drug Streptomycin. 
Introduction
Nucleoside and their derivatives have emerged as molecules with potentially useful therapeutic properties that have gained considerable attention from both synthetic and medicinal chemists due to their versatile biological activities in various therapeutic areas. Zidovudine (3 0 -azido-3 0 -deoxythymidine) was the first U.S. government-approved drug for the treatment of HIV, marketed under the brand name Retrovir (Fig 1) . Uridine derivatives are currently used as anti influenza drugs [1] . Over the past few years, several derivatives of the nucleosides are known to possess antimicrobial [2] , anticancer [3] , anti-inflammatory [4] and antiviral activities [5] [6] [7] [8] .
On the other hand, 1,2,3-triazole derivatives are known to exhibit significant biological activities such as antimicrobial [9, 10] , anticancer [11] , antioxidant [12] anti-HIV [13] , anti-inflammatory [14] , antiprotozoal [15] , anticonvulsant [16] , antihistamine [17] and anti-tubercular properties [18] . Such compounds have also been reported as b3-selective adrenergic receptor agonists [19] , kinase inhibitors [20] and other enzyme inhibitors [21] .
In continuation of our research toward the synthesis of biologically potent heterocyclic compounds [22, 23] , herein, we report the synthesis of Nucleoside (uridine) based 1,2, 3-triazole derivatives by using the Cu (I) Catalyzed Azide Alkyne Cyclization (CuAAC) reaction and their in vitro anticancer and anti bacterial activities.
Experimental section

General
Copper (I) iodide and propargyl bromide were purchased from Sigma-Aldrich and Cs 2 CO 3 was purchased from S.D. Fine Chemicals Limited. Thin-layer chromatography (TLC) was performed using Merck silica gel 60 F254 precoated plates (0.25 mm). Elemental analysis was performed on PerkinElmer 2400 Series II CHNS/O elemental analyzer. Melting points were determined using a Cintex apparatus and were uncorrected. FTIR spectra were recorded using a Bruker spectrometer and are reported in the frequency of absorption (cm À1 ). NMR ( 1 H & 13 C) spectra were recorded on 300 and 75 MHz instruments and CDCl 3 was used as solvent. 1 H NMR spectra were reported relative to Me 4 Si (d 0.0 ppm). Coupling constant (J) values are presented in Hertz and spin multiples are given as s (singlet), d (doublet), t (triplet), dd (doublets of doublet) and m (multiplet). Mass spectral measurements were carried out by EI method on a Jeol JMC-300 spectrometer at 70 eV.
Synthesis
Synthesis of 2
0 ,3 0 -O-(1-Methylethylidene)-3-(2-propyn-1-yl)uridine (2) To a stirred solution of 2 0 ,3 0 -O-(1-Methylethylidene)uridine (5 g, 17.60 mmol) in acetonitrile (100 mL) were added propargyl bromide (2.44 mL, 22.00 mmol) and cesium carbonate (5.72 g, 17.60 mmol) and stirred at room temperature for 30 min. Then, the reaction mixture was filtered and concentrated under reduced pressure to afford crude compound. The crude was diluted with H 2 O (50 mL) and extracted with CHCl 3 (3 Â 50 mL). The combined organic layer was washed with brine, dried over Na 2 SO 4 and the resulted residue was purified by column chromatography (SiO 2 , 2% MeOH-CHCl 3 ) to afford (4.48 g, 79 ± 1%) 2 0 ,3
2.2.2.
General procedure for synthesis of 1,4-disubstituted 1,2,3-triazole derivatives (3a-3n)
To a solution of aryl amine (ArNH 2 , 1 mmol, 1.2 eq) in conc. HCl (5 ml) was added an aqueous solution of NaNO 2 (3 eq) and stirred for 30 min at 0-5°C. Then, an aqueous solution of NaN 3 (1.5 eq) was added slowly at 0-5°C and stirred for another 30 min. After completion of the reaction by TLC analysis, the crude mixture containing the azido derivative was added to a mixture of compound-2 (1 eq) and CuI (5 mol%) in THF and the reaction mixture was stirred at room temperature for 6-12 h. The solvent was removed and the resulted residue was dissolved in CH 2 Cl 2 , washed with water (3 Â 20 mL), dried over Na 2 SO 4 and evaporated to afford the crude compounds. The crude compounds were purified by column chromatography using silica gel (100-200 mesh) and 2% MeOH-CHCl 3 system as an eluent to afford 1,2,3-triazole derivatives (3a-3n) in good yields. 
Assay of in vitro anticancer activity
The synthesized compounds were evaluated for their in vitro anticancer activity against two different human cancer cell lines, i.e. breast cancer cell line (MCF-7) and cervical carcinoma cell line (HeLa). Cell viability in the presence of the test samples were measured by the MTT-microcultured tetrazolium assay [27] . This assay is a quantitative colorimetric method for the determination of cell viability. The assessed parameter is the metabolic activity of viable cells. Metabolically active cells reduce the pale yellow tetrazolium salt (MTT) to a dark blue water-insoluble formazan, which can be directly quantified after solubilization with DMSO. The absorbance of formazan directly correlates with the number of viable cells. MCF-7 and HeLa cells were plated into a 96-well plate at a density of 1x10 4 cells/well. Cells were grown overnight in the full medium and then switched to the low serum media. DMSO was used as control. After 48 h of treatment with different concentrations of test compounds, the cells were incubated with MTT (2.5 mg/mL) in the CO 2 chamber for 2 h. The medium was then removed and 100 lL of DMSO was added into each well to dissolve formazan crystals. After thoroughly mixing, the plates were read at 570 nm for optical density which is directly correlated with cell quantity. The results were represented as percentage of viability. All the experiments were carried out in triplicate. The response parameter calculated was the IC 50 value, which corresponds to the concentration required for 50% inhibition of cell viability.
Assay of in vitro antibacterial activity
The minimum inhibitory concentrations (MIC) of synthesized compounds (3a-3n) were tested against Gram-positive organisms such as Staphylococcus aureus (MTCC 96) and Bacillus subtilis (MTCC 441) and gram negative bacteria Escherichia coli (MTCC 443) and Proteus vulgaris (MTCC 1771) by the broth dilution method recommended by the National Committee for Clinical Laboratory (NCCL) standards [28] . Serial dilutions of the test compounds were performed at concentrations ranging from 150 to 0.58 lg mL À1 in a 200 mL culture medium final volume. Afterward each well was seeded with a 50 lL microbial suspension of 0.5 MacFarland density. In each test a microbial culture control and a sterility control (negative) were performed. The plates were incubated for 24 h at 37°C. The lowest concentration which inhibited the visible microbial growth was considered the MIC.
Results and discussion
Chemistry
The synthetic route for the preparation of uridine derived 1,2,3-triazoles is depicted in Scheme 1. 2 0 ,3 0 -O-(isopropylidene) uridine was subjected to propargylation using propargyl bromide in the presence of Cs 2 CO 3 to yield (79 ± 1%) of the compound-2 [24] . Aryl azides were synthesized from diazonium salts of aryl amines and NaN 3 [25] . Compounds (3a-3n) were synthesized by the treatment of 2 0 , 3 0 -O-(isopropyli dene)-3-(2-propyn-1-yl) uridine (2) with aryl azides in the presence of catalytic amount of CuI in THF at room temperature [26] . 2 0 ,3 0 -O-(isopropylidene) uridine was used instead of Uridine to simplify the reaction. Uridine on direct alkylation yielded only 20-25% N-propargyl product.
All the crude compounds were purified by column chromatography using silica gel (60-120 mesh) and 2% MeOH in C NMR spectra confirmed the formation of the triazole ring. Similarly, the molecular ion peak from the mass spectra and elemental analyses data are further evidence for the formation of the products.
In vitro anticancer activity
The examination of anticancer activity results (Table 1) revealed that, compound derived from 2-hydroxy methyl-5-fluoro phenyl on the triazole ring, i.e., 3d has exhibited excellent activity against MCF-7 (IC 50 : 11.34 lM) and good activity against HeLa (IC 50 : 16.48 lM) when comparing with the standard drug Cisplatin. Compound derived from 4-chloro phenyl on the triazole ring, i.e., 3f has exhibited excellent activity against MCF-7 (IC 50 : 11.73 lM). Compound 3n, bearing 2, 6-dibromo-4-fluoro group on the triazole ring against Hela (IC 50 :7.93 lM), 3b and 3c against MCF-7 (IC 50 :14.20 and 18.58 lM) have shown good activity. The remaining compounds have exhibited moderate activity against both cancer cell lines ranging from 20.21 to >200 lM. 
In vitro antibacterial activity
The minimum inhibitory concentrations (MIC) of synthesized compounds (3a-3n) were tested against Gram-positive and Gram negative bacteria. The antibacterial activity screening results (Table 2) revealed that, compounds possessing the napthyl group and 2, 6-dibromo-4-chloro phenyl group on the triazole ring (3b and 3n) have shown excellent activity against E. coli and B. Subtilis when comparing with the standard drug Streptomycin. Compound 3d against P. vulgaris, 3k against S. aureus, and compound 3l against S. aureus and B. subtilis have shown promising antibacterial activity.
Structure-activity relationship of the compounds (3a-3n) revealed that, the 1st position of the triazole ring bearing napthyl (3b), 2-hydroxymethyl 5-fluoro phenyl (3d), 3-chloro phenyl (3k), 3,5-dichloro phenyl (3l) and 2,6-dibromo-4-fluoro phenyl (3n) were found to be potent antibacterial agents and the compounds bearing 4-methoxy phenyl (3a) and 2-chloro-5-nitro phenyl (3c) were found to be moderate antibacterial agents than the remaining compounds.
Conclusion
In summary, we have designed and synthesized a series of novel 1, 2, 3-triazole clubbed uridine hybrids and evaluated for their anticancer and antibacterial activities. Among the series, compounds 3d and 3f have shown potent activity against breast cancer cell line-MCF-7 and compound 3n has shown excellent activity against cervical carcinoma cell line (HeLa) than the standard drug Cisplatin. The active compounds can be considered as future drug candidates for cancer therapy, and by effecting a simple modification in the structure a new potent analog can be generated that has desired anticancer activity with good efficacy. Similarly, compounds 3b and 3n have shown marked antibacterial activity against E. coli & B. subtilis, 3d against S. aureus, 3k against S. aureus & B. subtilis and 3l against P. vulgaris have shown very good antibacterial activity. 
